The science of investing

director/

11 August 2006
| By Sara Rich |

Despite attracting negative sentiment in the past, Australia’s biotechnology sector will grow significantly over the next decade, offering appealing opportunities to astute investors, according to eG Capital director Brad Ross-Sampson.

The nation is ranked sixth in the world in terms of the number of biotech companies it has, including three organisations that have positioned themselves as dominant global players.

“I think the biotech revolution is here to stay and Australia is very much a part of the revolution, underpinned by its medical research and innovation,” Ross-Sampson said.

He said the sector had experienced underperformance in recent years due to a combination of factors, such as the resource boom and negative media coverage, but predicts this will change as the sector matures.

“Where Australia has failed in recent times is in attracting the right managers to market these companies globally,” Ross-Sampson said.

“But the sector has matured and progressed and now is the ideal time to invest in these stories.

“As time goes on the media will take more interest in biotech and it will become more mainstream.”

He made these comments while launching the eG Capital BioEquities Fund, which is now open to retail and wholesale investors.

The fund is a sector-specific fund investing in Australian listed biotech and life science companies, with an objective to achieve returns that exceed the S&P/ASX 300 Accumulation Index over the medium to long-term.

“The fund is just a natural progression of the sector becoming more efficient,” Ross-Sampson said.

“We recognise the investment opportunities to be found in the biotech and life science sector and strongly believe in the long-term viability of the sector.”

Read more about:

AUTHOR

Recommended for you

sub-bgsidebar subscription

Never miss the latest news and developments in wealth management industry

MARKET INSIGHTS

So we are now underwriting criminal scams?...

5 months ago

Glad to see the back of you Steve. You made financial more expensive, not more affordable as you claim, and presided ...

5 months 1 week ago

Completely agree Peter. The definition of 'significant change is circumstances relevant to the scope of the advice' is s...

7 months 1 week ago

The FSCP has issued a written direction to an adviser who charged clients “extraordinary fees” for inappropriate and conflicted advice, as well as encouraged them to swit...

1 week 6 days ago

ASIC has cancelled the AFSL of an advice firm associated with Shield and First Guardian collapses, and permanently banned its responsible manager. ...

3 weeks 2 days ago

ASIC has confirmed the industry funding levy for the 2024–25 financial year, and how much licensees can expect to pay....

3 days 23 hours ago

TOP PERFORMING FUNDS

ACS FIXED INT - AUSTRALIA/GLOBAL BOND
Fund name
3y(%)pa
2
DomaCom DFS Mortgage
95.46 3 y p.a(%)
5